• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

7 Drugs Approved for Primary Care: Q2 2024

News
Slideshow

As another quarter rounds out, a new batch of drugs have been approved by the US Food and Drug Administration for conditions often seen in primary care - quite a few of them first-in-class or novel in another way. For example, the first and only pneumococcal vaccine formulated specifically to protect adults 50 years and older; the first mRNA vaccine against RSV for adults aged 60 years and older; and the first inhaled product with a novel mechanism of action approved for maintenance chronic obstructive pulmonary disease (COPD) treatment in over 20 years. In the slides below, we recap these drugs and 5 more.


Missed last quarter's drug roundup? Check out 7 Drugs Approved for Primary Care: Q1 2024

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
© 2025 MJH Life Sciences

All rights reserved.